Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11991519 | 0.92 | KMT2A (0.35) | KMT2AATMCFTRLMNAKDM4E | |
| SCHEMBL11991535 | 0.92 | KMT2A (0.35) | KMT2AATMCFTRLMNAKDM4E | |
| SCHEMBL12946090 | 0.86 | DRD1 (0.34) | HCAR3LMNA | |
| SCHEMBL11992930 | 0.85 | SCN9A (0.45) | SCN9AFPR2 | |
| SCHEMBL11992926 | 0.84 | KMT2A (0.34) | KMT2AATMHCAR3CFTRLMNA | |
| SCHEMBL11992587 | 0.83 | KMT2A (0.33) | KMT2AATMHCAR3CFTRLMNA | |
| SCHEMBL11922620 | 0.79 | KMT2A (0.36) | KMT2AATMCFTRLMNAKDM4E | |
| SCHEMBL11992979 | 0.77 | DHODH (0.35) | HCAR3LMNAKDM4EMAPK10AAK1 | |
| SCHEMBL11991522 | 0.77 | ABL1 (0.33) | KMT2AATMSCN9A | |
| SCHEMBL11991464 | 0.77 | SCN9A (0.45) | SCN9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912182-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8541402-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2009076747-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | KMT2A 1862/4885ATM 4155/4885HCAR3 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.